drugset / Trial / NCT06687551

JAK Inhibitor Dose TAPering Strategy Study

NCT06687551 ↗

Phase 4 Not yet recruiting 308 enrolled University Hospital, Toulouse
RandomizedParallel-groupSingle-blindTreatment

Summary

This study aims to assess the feasibility of tapering JAK inhibitors in rheumatoid arthritis patients in low disease activity by comparing a group of patients tapering the JAK inhibitor dosage to a group of patients continuing the full-dose. Participants will: * Either take 1. JAK inhibitor dose-tapering strategy. 2. JAK inhibitor continuous therapy strategy. * Visit the clinic once every 3 months for checkups and tests * Keep a diary of their treatment intake and symptoms

Timeline

Start
2025-01-01
Primary completion
2029-04-01
Completion
2029-04-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Baricitinib Small molecule 2 mg —
Comparator Baricitinib Small molecule 4 mg —
Comparator Filgotinib Small molecule 100 mg —
Comparator Filgotinib Small molecule 200 mg —
Comparator Tofacitinib Small molecule 5 mg —
Comparator Tofacitinib Small molecule 11 mg —
Comparator Upadacitinib Small molecule 15 mg —

Indications